2 results
Approved WMOWill not start
Sub-study APhase 1b:To assess the DLT rate and estimate the MTD of sasanlimab in combination with encorafenib and binimetinib to determine the RP2D for the combination. Phase 2:To assess the durable ORR of sasanlimab in combination with encorafenib…
Approved WMORecruiting
To determine the effectiveness of more intensive BP lowering provided by a *Triple Pill* strategy on top of standard of care, on the time to first occurrence of recurrent stroke after ICH.